Martin Dekker - 07 Jun 2023 Form 4 Insider Report for Bellerophon Therapeutics, Inc.

Reporting relationship: VP of Engineering & Manufacturing
Issuer ticker: N/A
Reported as of: 07 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2023, 16:11:29 UTC
Prior SEC filing: 14 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Martin Dekker

Key filing fact

Martin Dekker filed Form 4 for Bellerophon Therapeutics, Inc. on 09 Jun 2023.

Key facts

This page summarizes Martin Dekker's Form 4 filing for Bellerophon Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2023, 16:11.

Change

Previous filing in this sequence was filed on 14 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BLPH transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: -50,000
Change %: -50%
Price: $0.000000
Shares after: 50,000
Date: 07 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $0.8264
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option was approved by the Compensation Committee of the Board of Directors of Bellerophon Therapeutics, Inc., on February 10, 2023, contingent upon stockholder approval of an amendment to the Company's 2015 Equity Incentive Plan under which the options were granted, which was approved by stockholders on June 7, 2023.

Footnote F2

This option vests in 16 quarterly installments commencing on the date hereof.

SEC remarks

VP of Engineering & Manufacturing